Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer
Brain metastases remain a critical issue in the management of non-small cell lung cancer (NSCLC) because of the high frequency and poor prognosis, with survival rates often measured in just months. The local treatment approach remains the current standard of care, but management of multiple asymptom...
Main Authors: | Likui Fang, Wuchen Zhao, Bo Ye, Da Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.670313/full |
Similar Items
-
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
by: Yuxiao Song, et al.
Published: (2020-08-01) -
Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a ‘Real-Life’ Setting
by: Marcus Skribek, et al.
Published: (2020-12-01) -
The Effect of Asymptomatic and/or Treated Brain Metastases on Efficacy of Immune Checkpoint Inhibitors in Metastatic Non–Small Cell Lung Cancer: A Meta-Analysis
by: Sihan Li, et al.
Published: (2021-06-01) -
Advances in Combination Therapy of Immune Checkpoint Inhibitors for Lung Cancer
by: Hanfei GUO, et al.
Published: (2020-02-01) -
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases
by: Eric J. Lehrer, et al.
Published: (2018-10-01)